metsera glp-1 Metsera's Receptor Agonist MET-097i Pfizer Acquires a GLP-1 Pipeline

In the 2023 New England Journal of Medicine trial, the retatrutide treatment groups showed not only gastrointestinal abnormalities but also a dose-dependent increase in heart rate

Furthermore, its short half-life of less than 3 h (Min et al., 2025) necessitates twice-daily injections to maintain efficacy, which can be a limiting factor for long-term patient adherence

Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes

This isn't about just listing side effects

Bottom Line Calibrate is not for those looking for a miracle weight-loss solution

In 2005, a new treatment of T2DM based on the action of GLP-1 was introduced (137)